During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Nada Hamad, St Vincent's Hospital Sydney, Sydney, AU, and Silvy Lachance, Hôpital Maisonneuve-Rosemont, Montreal, CA. We asked, How can patient-reported QoL change our view on unmet needs in GvHD?

The main topic of this podcast is about documenting the quality of life (QoL) of patients with acute and chronic GvHD. Lachance focuses on patient-reported outcomes regarding the impact GvHD has on aspects of daily life. Research has demonstrated that GvHD severity, long term corticoid treatment, or being corticoid resistant have a significant impact on QoL.

Hamad continues the conversation by exploring the stress of survival for patients undergoing bone marrow transplantation. She believes that patient self-reported symptoms should direct future research on GvHD treatment and prevention. 

Hosted on Acast. See acast.com/privacy for more information.